AcuCort AB is a Sweden-based pharmaceutical company. The company develops oral films ISICORT, which involve chemical substance glucocorticoid dexamethasone that is used for the treatment of acute allergic reactions, as well as for nausea and vomiting during chemotherapy treatments. AcuCort AB operates mostly in Nordic countries.

Employees

Sector

Drug Retailers

More about the company

Quotes

Date	Price	Change	Volume
26-09-04	SEK 0.6200	0.00%	238,348
26-09-03	SEK 0.6200	+2.65%	727,073
26-09-02	SEK 0.6040	-2.58%	48,155
26-09-01	SEK 0.6200	+3.33%	291,234
26-08-31	SEK 0.6000	0.00%	386,247

End-of-day quote SPOTLIGHT STOCK MARKET AB

More quotes

End-of-day quote SPOTLIGHT STOCK MARKET AB 2026-09-04			5-day change	1st Jan Change
0.6200 ^SEK	0.00%		+3.33%	+3.33%

09-01	Acucort's warrant program was fully subscribed	FW
08-26	Acucort study published in scientific journal	FW

Market Cap	145M 15.19M 13.07M 12.3M 11.24M 21.02M 1.43B 21.08M 56.4M 736M 57.05M 55.81M 2.37B	P/E 2024	-3.61x	P/E 2025	-5x
Enterprise Value	118M 12.37M 10.64M 10.01M 9.15M 17.11M 1.17B 17.16M 45.92M 599M 46.45M 45.44M 1.93B	EV / Sales 2024	129,716,884x	EV / Sales 2025	165,436,272x
Free-Float	67.11%	Yield 2024 *	-	Yield 2025	-

09-01	Acucort's warrant program was fully subscribed	FW
08-26	Acucort study published in scientific journal	FW
08-24	Acucort appoints Carl Frisk as Strategic Alliance Manager	FW
08-19	Acucort lifts revenue in Q2	FW
08-19	AcuCort AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-11	Acucort's phase IV study with Zeqmelit published	FW
08-11	Acucort Publishes Results from Phase Iv Study with Zeqmelit Oral Film	CI
08-07	Acucort postpones interim report to August 19	FW
07-27	AcuCort Receives Renewed FDA Small Business Waiver Ahead of Planned NDA Submission	CI
07-27	AcuCort Renews US FDA Small Business Waiver for New Drug Applications	MT
07-27	FDA waives application fee for Acucort	FW
06-11	Acucort sees increased partner interest ahead of BIO Convention in the U.S.	FW
05-27	AcuCort CEO: Focus on strengthening presence in existing markets, developing new partnerships, and advancing in the US	FW

09-01	AcuCort's warrant programme fully subscribed - key personnel to become shareholders in the company	AQ
08-31	AcuCort has published August 2026 newsletter	AQ
08-26	AcuCort: AcuCort study on patient preferences published in peer-reviewed scientific journal	PU
08-26	AcuCort study on patient preferences published in peer-reviewed scientific journal	AQ
08-24	AcuCort: AcuCort appoints Carl Frisk as Strategic Alliance Manager	PU

AcuCort AB Stock

Stocks

ACUC

SE0009695927

Drug Retailers

Valuation : AcuCort AB

Chart: AcuCort AB

Latest news : AcuCort AB

Press Releases : AcuCort AB

Quotes and Performance

Price Extremes

Managers and Directors : AcuCort AB

Other Drug Retailers

Financials

Company Profile

Quotes

1 week	+3.33%
Current month	+3.33%
1 month	-1.27%
3 months	-8.82%
6 months	-15.07%
Current year	+3.33%

1 week	0.56	0.64
1 month	0.5	0.66
Current year	0.4	0.95
1 year	0.4	0.95
3 years	0.33	1.26
5 years	0.33	4.98
10 years	0.33	9.5

Manager	Title	Age	Since
Jonas Jonas Jönmark CEO	Chief Executive Officer	55	2020-08-08
Anna Cherouvrier Hansson PRN	Corporate Officer/Principal	53	2025-10-13

Director	Title	Age	Since
Anna Maria Albertina Eriksrud BRD	Director/Board Member	68	2017-02-07
Ebba Cecilia Fåhraeus CHM	Chairman	63	2017-12-31
Göran Tornling BRD	Director/Board Member	79	2020-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACUCORT AB	0.00%	+3.33%	+4.03%	-1.27%	15.19M
JD HEALTH INTERNATIONAL INC.	+2.94%	+1.04%	-41.96%	-13.11%	15.07B
MATSUKIYOCOCOKARA & CO.	+0.44%	-1.03%	-18.22%	-9.97%	6.55B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	+3.29%	-0.16%	-51.62%	-33.19%	6.47B
YIFENG PHARMACY CHAIN CO., LTD.	+0.04%	+0.09%	-7.92%	-21.17%	4.14B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	+1.51%	+3.53%	+9.44%	-27.45%	3.19B
NAHDI MEDICAL COMPANY	-0.97%	-2.34%	-20.47%	-39.99%	3.17B
CLICKS GROUP LIMITED	-1.50%	-0.23%	-44.66%	-26.72%	2.94B
GUARDIAN PHARMACY SERVICES, INC.	+1.59%	+10.01%	+44.52%	-	2.58B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+2.42%	-5.49%	-16.90%	-10.30%	2.5B
Average	+0.98%	+0.96%	-14.38%	-20.35%	4.66B
Weighted average by Cap.	+1.63%	+0.54%	-25.99%	-20.07%

	2024	2025
Net sales	0.68 0.07 0.06 0.06 0.05 0.1 6.66 0.1 0.26 3.42 0.26 0.26 11.01	0.69 0.07 0.06 0.06 0.05 0.1 6.78 0.1 0.27 3.48 0.27 0.26 11.21
Net income	-17.4M -1.82M -1.56M -1.47M -1.34M -2.52M -172M -2.52M -6.75M -88.09M -6.83M -6.68M -284M	-26.19M -2.74M -2.36M -2.22M -2.02M -3.79M -258M -3.8M -10.16M -133M -10.28M -10.06M -427M
Net Debt	-2.77M -290K -249K -235K -214K -401K -27.36M -402K -1.08M -14.04M -1.09M -1.06M -45.22M	-27.01M -2.82M -2.43M -2.29M -2.09M -3.91M -267M -3.92M -10.48M -137M -10.6M -10.37M -441M